Zomedica Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Zomedica hat ein Gesamteigenkapital von $231.9M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $243.7M bzw. $11.8M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$79.51m
Eigenkapital	US$208.72m
Gesamtverbindlichkeiten	US$11.16m
Gesamtvermögen	US$219.88m

Jüngste Berichte zur Finanzlage

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: ZOMDie kurzfristigen Aktiva des Unternehmens ($92.1M) übersteigen seine kurzfristigen Passiva ($8.0M).

Langfristige Verbindlichkeiten: ZOMDie kurzfristigen Vermögenswerte des Unternehmens ($92.1M) übersteigen seine langfristigen Verbindlichkeiten ($3.8M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: ZOM ist schuldenfrei.

Schulden abbauen: ZOM hatte vor 5 Jahren keine Schulden.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: ZOM auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: ZOM verfügt über eine ausreichende Liquiditätsreserve für 2.2 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 15.7% pro Jahr abnimmt.

Zomedica Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Zomedica Receives Non-Compliance Notice from NYSE American

Recent updates

Zomedica's Assisi Loop Product Line Designated as Fear Free(TM) Preferred Product

Zomedica Corp. Introduces Enhanced Audio Features for the Vetguardian Zero-Touch Vital Signs Remote Monitoring System

Second quarter 2024 earnings released: US$0.024 loss per share (vs US$0.005 loss in 2Q 2023)

Zomedica Corp. Reiterates Financial Guidance for Full Year 2024

Zomedica Corp. Expands Truforma Addressable Market with Launch of Equine Cortisol Assay for the Platform

Senior Vice President of Sales recently bought US$105k worth of stock

Zomedica Corp. Releases Over-The-Air Software Update Capabilities for Its Truforma(R) Platform

Zomedica Corp. Provides Revenue Guidance for Full Year 2024

New minor risk - Share price stability

First quarter 2024 earnings released: US$0.009 loss per share (vs US$0.007 loss in 1Q 2023)

Zomedica Corp. to Report Q1, 2024 Results on May 09, 2024

Zomedica Corp., Annual General Meeting, Jun 06, 2024

Zomedica Corp. Provides Revenue Guidance for Full Year 2024

Full year 2023 earnings released: US$0.035 loss per share (vs US$0.017 loss in FY 2022)

Zomedica Corp. to Report Q4, 2023 Results on Apr 01, 2024

Zomedica Corp. Announces Publication of Research Con Including TRUFORMA(R) Platform Is More Accurate Diagnostic Test for Feline Hyperthyroidism Than Chemiluminescent Immunoassay (CLIA) Platform

New minor risk - Share price stability

Zomedica Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Full Year 2024

Zomedica Corp. Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease

Zomedica Announces Presentation of Clinical Data in Support of New Indications for Pulsevet Shock Wave Therapy

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.005 loss in 3Q 2022)

Zomedica Corp. to Report Q3, 2023 Results on Nov 13, 2023

Zomedica Corp. (NYSEAM:ZOM) acquired Qorvo Biotechnologies, LLC from Qorvo US, Inc.

Zomedica Corp. Launches its Newest Assay - Endogenous ACTH

Zomedica Receives Non-Compliance Notice from NYSE American

Second quarter 2023 earnings released: US$0.005 loss per share (vs US$0.005 loss in 2Q 2022)

High number of new directors

New major risk - Revenue and earnings growth

Zomedica Corp. Launches Revolutionary TRUVIEW(TM) Digital Microscope with Advanced Optics, Automated Slide Preparation, and Telepathology Services

First quarter 2023 earnings released: US$0.007 loss per share (vs US$0.004 loss in 1Q 2022)

Full year 2022 earnings released: US$0.017 loss per share (vs US$0.053 loss in FY 2021)

Zomedica Corp. to Report Q4, 2022 Results on Mar 15, 2023

Third quarter 2022 earnings released: US$0.005 loss per share (vs US$0.006 loss in 3Q 2021)

Zomedica Corp. to Report Q3, 2022 Results on Nov 14, 2022

Zomedica Corp. Announces Launch of Free T4 Assay for Truforma(R) Diagnostic Platform

Zomedica Corp. Appoints Pamela Nichols to Board of Directors and Audit and Governance Committees

Second quarter 2022 earnings released: US$0.005 loss per share (vs US$0.005 loss in 2Q 2021)

Zomedica Corp. (NYSEAM:ZOM) acquired Substantially All the Assets of Assisi Animal Health, LLC.

Zomedica Corp. Announces Management Changes

First quarter 2022 earnings released: US$0.004 loss per share (vs US$0.041 loss in 1Q 2021)

Zomedica Corp. Signs TRUFORMA Distribution Agreement with Miller Veterinary Supply

Zomedica Corp. Appoints Robert Cohen as Chief Executive Officer

Zomedica Corp. Appoints Ann Marie Cotter as Chief Financial Officer

Zomedica Pharmaceuticals Corp. Approves Board Appointments

Zomedica Pharmaceuticals Corp. has completed a Follow-on Equity Offering in the amount of $29.9975 million.

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen